Is Provenge "Reasonable And Necessary"? CMS Analysis For Medicare Coverage Seeks To Find Out
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare and Medicaid Services may consider setting formal parameters around Medicare coverage for Dendreon's ground-breaking prostate cancer vaccine Provenge next year.